Flow Markers

Question 1

Flow markers positive in AML typically

Answer 1

CD13, CD33, CD34, CD117

Question 2

Monoblastic floe markers

Answer 2

CD11c, CD14, CD64

Question 3

Erythroid differentiation markers

Answer 3

CD235 (glycophorin), CD36

Question 4

Megakaryoblastic differentiation markers

Answer 4

CD41, CD61

Question 5

Granulocytic differentiation markers

Answer 5

MPO, CD65

Question 6

CLL flow markers

Answer 6

Positive: weak surface ig, CD5, CD23
Important- strong CD 43+, CD 200

Negative: 79b, FMC7-

Question 7

Waldenstroms including genetic mutation

Answer 7

Positive: CD19, CD20, CD22 weak, CD25, CD79a and CD79b
Important: CD27, CD52

Equivocal: CD5, CD23

Negative: CD10, BCL6

MYD88 mutated 90%
CXCR4 30-40%
TP53 10%

Question 8

Waldenstroms including genetic mutation

Answer 8

Positive: CD19, CD20, CD22 weak, CD25, CD79a and CD79b
Important: CD27, CD52

Equivocal: CD5, CD23

Negative: CD10, BCL6

MYD88 mutated 90%
CXCR4 30-40%
TP53 10%

Question 9

Follicular lymphoma markers, cytogenetics and molecular

Answer 9

Positive: CD10, CD19, CD20, CD22, BCL2, BCL6

Variable: cyclin d1, CD43, k and l LV
CD21 and CD23 if nodular pattern

Negative: CD5, CD30

cytogenetics: characteristic t(14;18) IgH/BCL2 rearrangement

Molecular: KMT2D, EZH2, CARD11, RB1, FOXO1

Question 10

Mantle cell flow, cytogenetics, molecular

Answer 10

Pos: CD19, CD20, CD22, CD79a, FMC7, BCL2
Weak: CD5

Negative: CD23

Cytogenetics: t(11;14) upregulated cyclinD1 (due to bcl1 dysregulation via IgH chr14)

Molecular: ATM, CCND1, TP53 and NOTCH1
SOX11 associated with indolent disease

Question 11

DLBCL

Answer 11

pos: CD19, CD20, CD22, CD45 C-MYC (40% cut off), BCL2 (50%), BCL6 (GC MARKER)

Weak/variant: CD10 in GC, EBV

Negative: CD5, CD23, CD25, TdT

Cytogenetics/mol: BCL2, BCL6 translocations. MYC (Double or triple hit)

Question 12

Primary CNS lymphoma

Answer 12

Pos: B cell markers, CD45, BCL2 and 6, MUM1, IRF4, MYC

Neg: TdT, CD10, CD30, CD38, CD138

Cyto/mol: MYD88 and BCL6 rearrangements/mutations

Question 13

Primary mediating B cell lymphoma

Answer 13

Pos: CD19, CD20, CD22, 79B

variable: CD30

neg: EBV CD5 sIgM, CD15

Cytogenetics/molecular: 9q amplification of genes CD274 and PDCDILG2.
Dysregulation of JAKSTAT and NFkB pathway

Question 14

Marginal zone flow

Answer 14

Pos: CD19, FMC7

weak/variable: CD103, MALT, BCL10

Neg: CD5, CD11c, CD23, CD25, BCL2

Question 15

Splenic marginal zone flow and cytogenetics

Answer 15

Pos: CD19, 20, 79b, SmIg, FMC7, klc restricted

Weak/variable: CD23

Neg: CD5, CD10, 11c, CD25, CD103

Cytogenetics: 7q del, but highly varied

Question 16

MALT cytogenetics

Answer 16

T(11;18), t(1;14) poor response to h pylori eradication

Question 17

Burkitts

Answer 17

Pos: CD10, 19, 20, 22, BCL6, Smlg, 81, 38, BCL6, 79a

Neg: CD5, CD23 and TdT and BCL2

Ki67 >99%

Cytogenetics: t(8;14) mycigh, t(2;8)myc-llc t(14;18) myc-klc latter is poor prognosis

Question 18

Peripheral t cell lymphoma NOS

Answer 18

Pos: CD4, 8 with TCR rearrangement and clonality

Neg: varies

Aberrant: CD5 and 7

Cyto/mol: loss 5q, 9q, 12q. Share gene expression as AITL. TCR rearrangements

Question 19

AITL

Answer 19

Pos: CD4, 10, 21 if follicular cells present, BCL6, CXCL13, CXCR3

neg: reduced CD8 compared to CD4. 3 AND 7 may be negative

Cyto: additional X chr, trisomy 5, IDH2, TET2, IRF4

Question 20

Anaplastic large cell lymphoma

Answer 20

Pos: EMA, TCR gebe rearrangements

variants: CD30 in alk+ve

Neg: CD3, EBV

Cyto: t(2;5) NPM1:ALK

Question 21

Sezary/MFU

Answer 21

Pos: CD2,3,4,45RO and CD8. TCR beta gene rearrangements

Variant: CD30

Neg: CD7 and 26

Question 22

Nk cell lymphoma

Answer 22

Pos: CD2, CD56, 3e EBV

Neg: no TCR rearrangement

Question 23

Enteropathy associated t-Cell lymphoma (EATL)

Answer 23

Pos: CD8, CD56, 3e, TIA-1

neg: EBV, CD4 ABD CD5

cyto type 1: +9q or -16q. Associated with HLADQ2
type 2: +1q, 5q, 8q

Question 24

Hepatosplenic t cell lymphoma

Answer 24

Pos: CD2, CD3, CD7, CD45, CD56 AND TIA-1

neg: CD4, CD5, CD8, EBV

Cyto: gamma-delta T cell receptor expression and isochrome 7q.
Alpha beta t cell receptor variant
Mutations activating JAK/STAT pathway

Question 25

Subcutaneous penniculitjs t cell lymphoma

Answer 25

Pos: CD3, CD8. Can be 8+56- or vice versa

Neg: CD 4, 30 and EBV

Question 26

Hodgkin lymphoma

Answer 26

pos: CD15, CD30, PAX5, PD-L1

Variable: EBV, CD20 in NLPHL (popcorn cells)

neg: CD2, 3,10,45

Cytogenetics: BTK, CARD11 and BCL10